Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-04-10 09:37 am Sale |
2023-04-06 | 13G | Rubius Therapeutics, Inc. RUBY |
FMR CORP | 298,019 0.329% |
-12,078,134 (-97.59%) |
Filing History |
| 2023-03-03 11:28 am Sale |
2023-02-28 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 0 0.000% |
-4,869,126 (Position Closed) |
Filing History |
| 2023-02-14 1:00 pm Purchase |
2022-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
Flagship VentureLabs IV LLC | 38,606,526 42.700% |
38,606,526 (New Position) |
Filing History |
| 2023-02-09 12:31 pm Sale |
2023-02-09 | 13G | Rubius Therapeutics, Inc. RUBY |
FMR CORP | 12,376,153 13.694% |
-1,103,713 (-8.19%) |
Filing History |
| 2023-01-20 07:32 am Sale |
2022-12-30 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 4,869,126 5.390% |
-61,733 (-1.25%) |
Filing History |
| 2022-02-14 3:00 pm Purchase |
2021-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
Flagship Ventures Fund IV General Partner LLC | 38,581,526 42.900% |
241,250 (+0.63%) |
Filing History |
| 2022-02-11 06:36 am Sale |
2021-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
Artal International Management S.A. | 3,701,580 4.100% |
-782,211 (-17.45%) |
Filing History |
| 2022-02-09 10:24 am Purchase |
2022-02-08 | 13G | Rubius Therapeutics, Inc. RUBY |
FMR CORP | 13,479,866 14.999% |
2,101,599 (+18.47%) |
Filing History |
| 2022-01-26 06:55 am Purchase |
2021-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 4,930,859 5.490% |
220,798 (+4.69%) |
Filing History |
| 2021-03-08 4:30 pm Purchase |
2021-02-26 | 13G | Rubius Therapeutics, Inc. RUBY |
Artal International Management S.A. | 4,483,791 5.500% |
4,483,791 (New Position) |
Filing History |
| 2021-02-16 5:03 pm Purchase |
2020-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
Flagship Ventures Fund IV General Partner LLC | 38,340,276 47.400% |
43,750 (+0.11%) |
Filing History |
| 2021-02-16 1:00 pm Sale |
2021-02-16 | 13G | Rubius Therapeutics, Inc. RUBY |
Capital World Investors | 1,117,000 1.400% |
-4,060,000 (-78.42%) |
Filing History |
| 2021-02-08 10:31 am Purchase |
2021-02-05 | 13G | Rubius Therapeutics, Inc. RUBY |
FMR CORP | 11,378,267 14.060% |
2,210,975 (+24.12%) |
Filing History |
| 2021-01-27 12:12 pm Purchase |
2020-12-31 | 13G | Rubius Therapeutics, Inc. RUBY |
BAILLIE GIFFORD & CO | 4,710,061 5.820% |
458,591 (+10.79%) |
Filing History |